Xeris Biopharma (XERS) Dives 1.72% to Month Low as Earnings Loom and Recorlev Growth Fuels Caution

The share price fell to its lowest level since the beginning of the month today, with an intraday decline of 1.72%.

Xeris Biopharma (XERS) is set to report Q3 2025 earnings on November 6, with revenue projected to rise 36.6% year-over-year to $74.19 million. Analysts have revised revenue estimates upward four times in the past three months, reflecting confidence in the company’s ability to meet or exceed expectations. The stock’s recent weakness comes amid heightened anticipation for results, as the market weighs the impact of its flagship product, Recorlev, which drove 49% growth in Q2 and underpins a raised 2025 revenue guidance of $280 million–$290 million. Despite these fundamentals, shares remain pressured ahead of the earnings release, signaling caution among investors.

Recorlev’s performance remains a critical factor for Xeris, with its once-weekly formulation offering a competitive edge in the acromegaly treatment market. The drug’s success has solidified the company’s position in specialty pharmaceuticals, a sector favoring high-margin, niche therapies. However, the stock’s decline to a multi-month low highlights sensitivity to near-term results and valuation concerns. With a Seeking Alpha Quant Rating indicating strong analyst sentiment, the focus now shifts to whether Xeris can deliver on its revised guidance and sustain momentum. A positive earnings report could reignite investor optimism, but any shortfall risks exacerbating downward pressure, particularly in a market increasingly scrutinizing growth sustainability in biotech firms.

{}